SpringWorks Therapeutics SWTX 深 沪
等待开盘 04-02 09:30:00 美东时间
46.99
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 46.99
- 总市值 35.41亿
- 52周最高 62.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 28.21
- 委 比 0.00%
- 总股本 7534.90万
- 历史最高 96.48
- 量 比 0
- 振 幅 0.00%
- 历史最低 13.60
- 每 手 1
- 风险率 3.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Merck FY 2025 operating cash flow falls 14.3% to EUR 3.9 billion
Merck FY 2025 operating cash flow falls 14.3% to EUR 3.9 billion Merck KGaA reported FY 2025 net sales of EUR 21.1 billion (organic growth +3.1%; reported -0.3%), with foreign exchange effects of -3.7%. FY 2025 EBITDA pre was EUR 6.1 billion (organic growth +5.6%), and the EBITDA pre margin was 28.9
03-05 14:16
Merck Q4 net income drops -52.1% to EUR 319 million
Merck Q4 net income drops -52.1% to EUR 319 million Merck KGaA reported FY 2025 net sales of EUR 21.1 billion (-0.3%) and EBITDA pre of EUR 6.1 billion (+0.6%), with an EBITDA pre margin of 28.9% (up 0.2pp). EPS pre was EUR 8.34 (-3.4%). Operating cash flow was EUR 3.9 billion (-14.3%), and net fina
03-05 14:16
Merck KGaA Publishes 2025 Annual Report
Merck KGaA Publishes 2025 Annual Report Merck KGaA, Darmstadt, Germany published its 2025 annual report, outlining moderate organic net sales growth and solid profitability for the year, with contributions from Life Science, Healthcare and Electronics. The company reported that Life Science returned
03-05 14:16
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
Dr. Freda Lewis-Hall, a prominent psychiatrist and biopharmaceutical executive, has been appointed to Helus Pharma's Board of Directors and will also serve as Chair of the Scientific Advisory Committee. With over 40 years of experience, she will guide the company's clinical development strategy, regulatory engagement, and translational rigor across its novel serotonergic agonist portfolio. Helus Pharma is focused on developing innovative treatmen...
02-24 12:45
Edgewise Therapeutics Appoints Michael Nofi as Chief Financial Officer
Edgewise Therapeutics Inc. has appointed Michael Nofi as Chief Financial Officer, effective November 10, 2025. Nofi succeeds R. Michael Carruthers, who is retiring. Nofi previously served as Chief Acc...
2025-11-10 21:02
UPDATE 3-Germany's Merck eyes life science deals, but muted 2026 outlook knocks shares
Recasts with details on 2026 guidance in paragraphs 1-3, updates share move in paragraph 4 Merck provides 2026 and mid-term forecasts, confirms targets for 2025 Company is ready for more M&A with focu...
2025-10-16 13:29
UPDATE 3-Drug developer MapLight eyes $704.3 million valuation in US IPO
Adds analyst comments in paragraphs 4, 6 and 8 By Prakhar Srivastava Oct 6 (Reuters) - MapLight Therapeutics, a clinical-stage biotech backed by Novo Holdings, said on Monday it is targeting a valuati...
2025-10-07 04:19
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
SpringWorks Therapeutics announced that the European Commission has granted marketing authorization for OGSIVEO® (nirogacestat) as the first and only therapy approved in the EU for the treatment of adults with progressing desmoid tumors requiring systemic treatment. The approval is based on the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival (PFS), objective response rate (ORR), and patient-reported ou...
2025-08-18 13:10
